Business Context and Reporting Period
Company: Compugen Ltd.
Filing Type: Form 20-F (Annual Report)
Period Ended: December 31, 2004
Business Overview: Compugen is a drug and diagnostic discovery company based in Israel, utilizing computational biology, mathematics, and physics to identify therapeutic proteins and diagnostic markers. The company has shifted its strategy from selling software tools (e.g., LEADS, Genecarta) to focusing on internal discovery pipelines and licensing product candidates to pharmaceutical and biotechnology partners.
Key Financial Metrics
| Metric ($ in thousands) | 2004 | 2003 |
|---|---|---|
| Revenues | 2,630 | 6,776 |
| Governmental and Other Grants | 1,397 | 2,050 |
| Total Revenues and Grants | 4,027 | 8,826 |
| Total Operating Expenses | 19,604 | 23,042 |
| Operating Loss | (15,577) | (14,216) |
| Net Loss | (13,722) | (11,442) |
| Cash and Cash Equivalents | 4,366 | 7,910 |
| Short-term Marketable Securities | 16,208 | 8,797 |
| Long-term Marketable Securities | 27,854 | 43,803 |
| Total Liquid Assets | 48,428 | 60,510 |
| Accumulated Deficit | (105,756) | (92,034) |
| Shareholders' Equity | 49,566 | 59,808 |
Liquidity: As of December 31, 2004, the company held approximately $48.4 million in cash, cash equivalents, and marketable securities. Management projects these funds are sufficient to support operations for at least the next two years.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues and grants decreased by 54% to $4.0 million in 2004 from $8.8 million in 2003. This was driven by a 61% drop in commercial revenues due to the strategic shift away from selling software products (LEADS, Genecarta, OligoLibraries) and a 32% decrease in governmental grants.
- Expense Reduction: Total operating expenses decreased by 15% to $19.6 million. Research and Development (R&D) expenses fell 7% to $12.3 million, while Sales and Marketing expenses dropped 36% to $2.4 million following a reduction in the sales force.
- Increased Loss: Despite lower expenses, the Net Loss increased to $13.7 million (from $11.4 million) due to the significant revenue contraction and lower financial income ($1.4 million vs. $2.1 million in 2003).
- Strategic Restructuring: The company spun off its chemistry division into a wholly-owned subsidiary, Keddem Bioscience Ltd., in August 2004. Additionally, the company deconsolidated its majority-owned subsidiary, Evogene Ltd., effective July 1, 2003, and continues to account for it as an investment.
Guidance, Outlook, and Risks
Outlook: Compugen expects to continue incurring net losses in the near future as it invests heavily in R&D to advance its therapeutic and diagnostic pipelines. The company anticipates that R&D expenses will account for more than 60% of total operating expenses in 2005. Future revenue is expected to derive primarily from licensing agreements and milestone payments from collaborators rather than direct software sales.
Management Commentary:
- CEO Transition: In November 2004, CEO Dr. Mor Amitai announced his intention to resign, agreeing to remain until a successor is found or the end of 2005.
- Collaborations: The company entered a broad pipeline collaboration with Diagnostic Product Corporation in August 2004 focused on cancer and cardiovascular disease diagnostics.
- Government Grants: The company faces uncertainty regarding future funding from the Israeli Office of the Chief Scientist, with new funding deadlines set for June 30, 2005.
Risks and Contingencies:
- Profitability: The company has a history of losses and may never achieve profitability. It may require additional capital to fund operations beyond the next two years.
- Subsidiary Funding: Keddem Bioscience requires third-party funding to continue operations; failure to raise capital could result in the loss of the company's investment in this subsidiary.
- Intellectual Property: Risks include the inability to obtain patents for gene-based inventions and potential infringement claims from third parties.
- Geopolitical: Operations are concentrated in Israel, exposing the company to risks related to regional security, military service obligations of key employees, and currency fluctuations between the US Dollar and New Israeli Shekel.
Key Facts for Investor Verification
- Cash Runway: Verify if the $48.4 million in liquid assets remains sufficient given the burn rate of approximately $12.2 million in operating cash outflows for 2004.
- Grant Dependency: Assess the impact of the 32% reduction in Israeli government grants and the potential cessation of new funding after June 2005.
- Revenue Transition: Monitor the success of the new licensing strategy with Diagnostic Product Corporation and other potential partners to replace the lost software revenue stream.
- Leadership Stability: Track the progress of the CEO succession plan following Dr. Amitai's announced resignation.
- Subsidiary Viability: Evaluate the fundraising status of Keddem Bioscience Ltd., which holds the company's chemistry division assets.